
## Qiuzhong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3422824/publications.pdf Version: 2024-02-01



ΟШΖΗΟΝΟ

#	Article	IF	CITATIONS
1	Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. Cancer Chemotherapy and Pharmacology, 2022, 89, 209-215.	2.3	9
2	Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. , 2021, 9, e001696.		42
3	New nomograms to predict overall and cancerâ€specific survival of angiosarcoma. Cancer Medicine, 2021, 11, 74.	2.8	2
4	Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma. International Immunopharmacology, 2020, 89, 107139.	3.8	11
5	Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. Oncolmmunology, 2020, 9, 1752563.	4.6	15
6	CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2020, 69, 825-834.	4.2	14
7	<p>IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma</p> . Cancer Management and Research, 2019, Volume 11, 6691-6702.	1.9	24
8	PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228.		26
9	<i>TES</i> functions as a Menaâ€dependent tumor suppressor in gastric cancer carcinogenesis and metastasis. Cancer Communications, 2019, 39, 1-14.	9.2	7
10	PD-L1 expression patterns in tumour cells and their association with CD8 <sup>+</sup> tumour infiltrating lymphocytes in clear cell renal cell carcinoma. Journal of Cancer, 2019, 10, 1154-1161.	2.5	18
11	IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. Oncolmmunology, 2018, 7, e1373234.	4.6	47
12	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Management and Research, 2018, Volume 10, 6457-6468.	1.9	23
13	Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. Journal of Cancer, 2018, 9, 4204-4214.	2.5	4
14	Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort. Journal of Cancer, 2018, 9, 3447-3455.	2.5	11
15	Dendriticâ€cellâ€based immunotherapy evokes potent antiâ€tumor immune responses in CD105+ human renal cancer stem cells. Molecular Carcinogenesis, 2017, 56, 2499-2511.	2.7	14
16	Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer. Chinese Journal of Cancer, 2017, 36, 77.	4.9	26
17	Immunization-based scores as independent prognostic predictors in soft tissue sarcoma patients. Journal of Cancer, 2017, 8, 606-616.	2.5	3
18	Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. Oncotarget, 2016, 7, 6323-6334.	1.8	21

QIUZHONG

#	Article	lF	CITATIONS
19	The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. Journal of Cancer, 2016, 7, 626-632.	2.5	51
20	Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. Molecular Carcinogenesis, 2016, 55, 64-76.	2.7	24
21	Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget, 2016, 7, 16248-16261.	1.8	28
22	Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget, 2016, 7, 26670-26679.	1.8	51
23	A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma. Scientific Reports, 2015, 5, 9202.	3.3	22
24	Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Molecular Carcinogenesis, 2015, 54, 598-607.	2.7	53
25	Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncolmmunology, 2015, 4, e1038017.	4.6	14
26	Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells. Stem Cells, 2015, 33, 354-366.	3.2	54
27	A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. Oncotarget, 2015, 6, 27267-27274.	1.8	9
28	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget, 2015, 6, 41339-41349.	1.8	79
29	Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. Oncotarget, 2015, 6, 34800-34817.	1.8	46
30	Overexpression of WWP1 Promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget, 2015, 6, 40920-40933.	1.8	27
31	OKâ€432 synergizes with IFNâ€Î³ to confer dendritic cells with enhanced antitumor immunity. Immunology and Cell Biology, 2014, 92, 263-274.	2.3	3
32	Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. Scientific Reports, 2014, 4, 5177.	3.3	93
33	Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2013, 62, 1675-1685.	4.2	35